<DOC>
	<DOCNO>NCT01436955</DOCNO>
	<brief_summary>This multi-center , randomize double-blind , placebo-controlled study ass safety tolerability RG1662 individual Down Syndrome . Eligible subject randomize cohort receive either multiple oral dos RG1662 placebo . Anticipated time study treatment 38 day .</brief_summary>
	<brief_title>A Study RG1662 Individuals With Down Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Adult individual , 18 30 year age , diagnosis Down Syndrome ( confirm karyotype ) Males nonpregnant nonlactating female Parent legal guardian/representative caregiver willing give write informed consent Subject willing assent consent participate Major depressive disorder adequately control selective serotonin reuptake inhibitor serotonin norepinephrine reuptake inhibitor Subjects meeting clinical diagnostic criterion autistic spectrum disorder , attention deficit hyperactivity disorder unlikely cooperate take part successfully study assessment Subjects primary psychiatric diagnosis Subjects evidence meeting clinical diagnosis dementia Subjects personal history cardiac abnormality ; patient previously undergone congenital heart surgery enrol provide residual complication require intervention ( e.g . pace maker ) Subjects clinically significant obstructive pulmonary disease asthma adequately treat ( oral steroid allow ) Subjects thyroid dysfunction adequately control stabilized treatment least 8 week Subjects sustain elevated supine blood pressure ( SBP/DBP ) rest exceed 140/90 mmHg notable rest tachycardia ( mean HR &gt; 60 bpm ) blood pressure 90/40 mmHg Subjects take investigational medication within 3 month Body mass index ( BMI ) &gt; 40 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>